(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Brand names, (5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Analogs
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Brand Names Mixture
- No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Chemical_Formula
C20H30O2
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid RX_link
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid fda sheet
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid msds (material safety sheet)
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Synthesis Reference
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Molecular Weight
302.456 g/mol
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Melting Point
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid H2O Solubility
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid State
Oily Liquid
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid LogP
6.23 +/- 0.48
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Dosage Forms
Capsule (usually in fish oil in a combination with DHA)
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Indication
EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Pharmacology
Eicosanoids are chemical messengers derived from 20-carbon polyunsaturated fatty acids that play critical roles in immune and inflammatory responses. Both 20-carbon omega-6 fatty acids (arachidonic acid) and 20-carbon omega-3 fatty acids (EPA) can be found in cell membranes. During an inflammatory response, arachidonic acid and EPA are metabolized by enzymes known as cyclooxygenases and lipoxygenases to form eicosanoids. Increasing omega-3 fatty acid intake increases the EPA content of cell membranes and decreases the arachidonic acid content, resulting in higher proportions of eicosanoids derived from EPA. Physiologic responses to arachidonic acid-derived eicosanoids differ from responses to EPA-derived eicosanoids. In general, eicosanoids derived from EPA are less potent inducers of inflammation, blood vessel constriction, and clotting than eicosanoids derived from arachidonic acid.
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Absorption
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid side effects and Toxicity
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Patient Information
No information avaliable
(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid Organisms Affected
No information avaliable
